Trial Profile
Safety and efficacy of fixed dose combination of Elbasvir-Grazoprevir in patients with hepatitis C infection: A prospective, single-blind, real-life study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 21 May 2018 New trial record
- 10 May 2018 Results published in the Journal of Clinical Pharmacology